Evaluation of treatment response by Hopkins criteria on18F FDG PET-CT in patients of non-small cell lung cancer and its comparison with PERCIST response criteria

被引:0
|
作者
Dang, Shreya [1 ]
Shivdasani, Divya [1 ]
Pereira, Melvika [1 ]
Singh, Natasha [1 ]
Rungta, Rachita [1 ]
Roy, Debdip [1 ]
Kesariya, Jugal [1 ]
机构
[1] PD Hinduja Natl Hosp & Med Res Ctr, Dept Nucl Med & PET CT, Veer Savarkar Marg, Mumbai 400016, India
关键词
evaluation; FDG PET; Hopkins; NSCLC; PERCIST; response; POSITRON-EMISSION-TOMOGRAPHY;
D O I
10.1097/MNM.0000000000001756
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Aim To assess treatment response on FDG PET-CT in NSCLC patients by visual Hopkins score compared to PERCIST criteria and its potential for prognostication (or its correlation with survival).Methods Forty-four NSCLC patients with baseline and post-treatment FDG PET-CT scans were included, and interpreted using Hopkins and PERCIST criteria classifying patients into responders and non-responders. PERCIST-based CMR and PMR, and Hopkins Scores 1,2,3 were classified responders. PERCIST-based SD and PD and Hopkins scores 4,5 were classified as non-responders. Patients were followed upto 24 months after treatment completion. Cohen kappa for inter-criteria agreement and Kaplan Meir curve for overall survival (OS) analysis done.Results Out of 44 patients, PERCIST classified 27 (61.3%) as responders and 17 (38.6%) as non-responders, whereas Hopkins classified 12 patients (27.3%) as responders and 32 (72.7%) as non-responders. Inter-criteria agreement was low (kappa=0.19) with discordance in 45.5% of patients. Eighteen of 20 discordant cases were non-responders on Hopkins and responders on PERCIST, of which 88.8% were non-responders on follow-up as predicted by Hopkins. PERCIST responders had OS of 96.4% and 64.3% at 9 and 24 months, respectively, while non-responders OS was 93.5% and 40.2% at 9 and 24 months, respectively (P-value = 0.049). However, responders on Hopkins had OS of 100% at 24 months, whereas non-responders had OS of 93.5% and 51.5% at 9 and 24 months, respectively (P-value = 0.232).Conclusion Semi-quantitative PERCIST and visual Hopkins criteria show low inter-criteria agreement, with visual criteria better-predicting survival in patients of NSCLC.
引用
收藏
页码:1038 / 1045
页数:8
相关论文
共 50 条
  • [1] Comparison between CT-based and PERCIST criteria for evaluation of response to immune checkpoint inhibitors in Non-Small Cell Lung Cancer (NSCLC): is there a role for 18F-FDG PET/CT?
    Bauckneht, M.
    Rossi, G.
    Piva, R.
    Genova, C.
    Rijavec, E.
    Barletta, G.
    Biello, F.
    Menella, S.
    Dal Bello, M.
    Di Stefano, R.
    Cittadini, G.
    Merlo, D.
    Sambuceti, G.
    Grossi, F.
    Morbelli, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S51 - S51
  • [2] PET/CT evaluation of response to chemotherapy in non-small cell lung cancer: PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST)
    Ding, Qiyong
    Cheng, Xu
    Yang, Lu
    Zhang, Qingbo
    Chen, Jianwei
    Li, Tiannv
    Shi, Haibin
    JOURNAL OF THORACIC DISEASE, 2014, 6 (06) : 677 - 683
  • [3] Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria
    Ziai, D.
    Wagner, T.
    El Badaoui, A.
    Hitzel, A.
    Woillard, J. B.
    Melloni, B.
    Monteil, J.
    CANCER IMAGING, 2013, 13 (01) : 73 - 80
  • [4] Comparison of Lugano, PERCIST, and RECIL criteria in DLBCL response assessments of 18F-FDG PET/CT
    Tang, Pan
    Su, Minggang
    Tian, Rong
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [5] Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer
    de Geus-Oei, Lioe-Fee
    van der Heijden, Henricus F. M.
    Visser, Eric P.
    Hermsen, Rick
    van Hoorn, Bas A.
    Timmer-Bonte, Johanna N. H.
    Willemsen, Antoon T.
    Pruim, Jan
    Corstens, Frans H. M.
    Krabbe, Paul F. M.
    Oyen, Wim J. G.
    JOURNAL OF NUCLEAR MEDICINE, 2007, 48 (10) : 1592 - 1598
  • [6] EVALUATION OF ERLOTINIB TREATMENT RESPONSE IN NON-SMALL CELL LUNG CANCER USING EORTC METABOLIC CRITERIA, PERCIST AND ANATOMIC CRITERIA RECIST
    Ippolito, Massimo
    Stefano, A.
    Cosentino, Sebastiano
    Mure', G.
    Russo, G.
    Baldari, S.
    Bordonaro, Roberto
    Sabini, M. G.
    Sardina, D.
    Messa, C.
    Ghilardi, M. C.
    Valastro, I.
    Soto Parra, Hector J.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1273 - S1273
  • [7] Accuracy of [18F]FDG PET-CT in the evaluation of the post-neoadjuvant local response in esophageal cancer by using cualitative and PERCIST criteria
    Martin Aguilar, S.
    Ponce Herrera, C.
    Montiel Casado, C.
    Moreno Ruiz, F.
    Florez Rial, M.
    Requena Santos, M.
    Gutierrez Cardo, A.
    Marin Parrilla, V.
    Nicolas Aguado, M.
    Alvarez Mena, N.
    Lumbreras Vega, L.
    Ramirez Ocana, D.
    Puentes Zarzuela, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S117 - S118
  • [8] The prediction of response to immunotherapy in non-small cell lung cancer patients by 18F-FDG PET/CT
    Evangelista, Laura
    JOURNAL OF THORACIC DISEASE, 2019, 11 (11) : E221 - E223
  • [9] 18F-FDG PET/CT: Therapy Response Assessment Interpretation (Hopkins Criteria) and Survival Outcomes in Lung Cancer Patients
    Sheikhbahaei, Sara
    Mena, Esther
    Marcus, Charles
    Wray, Rick
    Taghipour, Mehdi
    Subramaniam, Rathan M.
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (06) : 855 - 860
  • [10] Early response evaluation of gefitinib with F-18-FDG PET in patients with non-small cell lung cancer
    Ishikita, T.
    Oriuchi, N.
    Sunaga, N.
    Kaira, K.
    Higuchi, T.
    Miyakubo, M.
    Paudyal, B.
    Fukuda, J.
    Otake, H.
    Koyama, K.
    Endo, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S297 - S298